JAK2 disease-risk variants are gain of function and JAK signaling threshold determines innate receptor-induced proinflammatory cytokine secretion in macrophages

Journal of Immunology

Volumn 197, Issue 9, 2016, Pages 3695-3704

  Hedl, Matija ^a   Proctor, Deborah D ^a   Abraham, Clara ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 22; INTERLEUKIN 4; INTERLEUKIN 6; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN; PATTERN RECOGNITION RECEPTOR; THYMIC STROMAL LYMPHOPOIETIN; AUTACOID; CYTOKINE; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; PROTEIN KINASE INHIBITOR;

ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; CYTOKINE RELEASE; FLOW CYTOMETRY; GAIN OF FUNCTION MUTATION; GENE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFORMED CONSENT; JAK2 GENE; MACROPHAGE; MONOCYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; ULCERATIVE COLITIS; ADULT; ALLELE; CELL CULTURE; FEMALE; GENETICS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASE; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADULT; ALLELES; CELLS, CULTURED; CYTOKINES; FEMALE; GENOTYPE; HUMANS; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; JANUS KINASE 2; MACROPHAGES; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84992365437     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1600845     Document Type: Article

References (42)

1. Abraham, C., and J. H. Cho. 2009. Inflammatory bowel disease. N. Engl. J. Med. 361: 2066-2078.
2. Abraham, C., and R. Medzhitov. 2011. Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology 140: 1729-1737.
3. Barrett, J. C., S. Hansoul, D. L. Nicolae, J. H. Cho, R. H. Duerr, J. D. Rioux, S. R. Brant, M. S. Silverberg, K. D. Taylor, M. M. Barmada, et al; NIDDK IBD Genetics Consortium; Belgian-French IBD Consortium; Wellcome Trust Case Control Consortium. 2008. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40: 955-962.
4. Smythies, L. E., M. Sellers, R. H. Clements, M. Mosteller-Barnum, G. Meng, W. H. Benjamin, J. M. Orenstein, and P. D. Smith. 2005. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J. Clin. Invest. 115: 66-75.
5. Platt, A. M., C. C. Bain, Y. Bordon, D. P. Sester, and A. M. Mowat. 2010. An independent subset of TLR expressing CCR2-dependent macrophages promotes colonic inflammation. J. Immunol. 184: 6843-6854.
6. Zheng, S., and C. Abraham. 2013. NF-kB1 inhibits NOD2-induced cytokine secretion through ATF3-dependent mechanisms. Mol. Cell. Biol. 33: 4857-4871.
7. Hedl, M., J. Li, J. H. Cho, and C. Abraham. 2007. Chronic stimulation of NOD2 mediates tolerance to bacterial products. Proc. Natl. Acad. Sci. USA 104: 19440-19445.
8. Watanabe, T., N. Asano, P. J. Murray, K. Ozato, P. Tailor, I. J. Fuss, A. Kitani, and W. Strober. 2008. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J. Clin. Invest. 118: 545-559.
9. Bain, C. C., A. Bravo-Blas, C. L. Scott, E. Gomez Perdiguero, F. Geissmann, S. Henri, B. Malissen, L. C. Osborne, D. Artis, and A. M. Mowat. 2014. Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. Nat. Immunol. 15: 929-937.
10. Rivollier, A., J. He, A. Kole, V. Valatas, and B. L. Kelsall. 2012. Inflammation switches the differentiation program of Ly6Chi monocytes from anti-inflammatory macrophages to inflammatory dendritic cells in the colon. J. Exp. Med. 209: 139-155.
11. Neurath, M. F. 2014. Cytokines in inflammatory bowel disease. Nat. Rev. Immunol. 14: 329-342.
12. Wu, X., A. Lahiri, G. K. Haines, III, R. A. Flavell, and C. Abraham. 2014. NOD2 regulates CXCR3-dependent CD8+ T cell accumulation in intestinal tissues with acute injury. J. Immunol. 192: 3409-3418.
13. Kim, Y. G., N. Kamada, M. H. Shaw, N. Warner, G. Y. Chen, L. Franchi, and G. Núñez. 2011. The NOD2 sensor promotes intestinal pathogen eradication via the chemokine CCL2-dependent recruitment of inflammatory monocytes. Immunity 34: 769-780.
14. Lahiri, A., and C. Abraham. 2014. Activation of pattern recognition receptors up-regulates metallothioneins, thereby increasing intracellular accumulation of zinc, autophagy, and bacterial clearance by macrophages. Gastroenterology 147: 835-846.
15. Prager, M., J. Büttner, V. Haas, D. C. Baumgart, A. Sturm, M. Zeitz, and C. Büning. 2012. The JAK2 variant rs10758669 in Crohn's disease: altering the intestinal barrier as one mechanism of action. Int. J. Colorectal Dis. 27: 565-573.
16. O'Shea, J. J., and R. Plenge. 2012. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36: 542-550.
17. Sandborn, W. J., S. Ghosh, J. Panes, I. Vranic, C. Su, S. Rousell, and W. Niezychowski, and Study A 3921063 Investigators. 2012. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N. Engl. J. Med. 367: 616-624.
18. Sandborn, W., B. E. Sands, G. R. D'Haens, S. Vermeire, S. Schreiber, and S. Danese, J. Panés, B. G. Feagan, W. Reinisch, W. Niezychowski, G. Friedman, N. Lawendy, D. Yu, D. A. Woodworth, A. Mukherjee, P. J. Healey, H. Zhang, and C. Su. 2016. Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate to severe ulcerative colitis: results from two Phase 3 randomized controlled trials. Gastroenterology 150: S157.
19. Sandborn, W. J., S. Ghosh, J. Panes, I. Vranic, W. Wang, W. Niezychowski, and Study A 3921043 Investigators. 2014. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Clin. Gastroenterol. Hepatol. 12: 1485-1493.
20. Panés, J., W. Sandborn, S. Schreiber, B. E. Sands, S. Vermeire, G. Chan, M. Moscariello, W. Wang, W. Niezychowski, A. Marren, P. J. Healey, and E. Maller. 2016. Efficacy and safety of tofacitinib for oral induction therapy in patients with moderate to severe Crohn's disease: results of a Phase 2b randomized placebo-controlled trial Gastroenterology 150: S182-183.
21. Ghoreschi, K., M. I. Jesson, X. Li, J. L. Lee, S. Ghosh, J. W. Alsup, J. D. Warner, M. Tanaka, S. M. Steward-Tharp, M. Gadina, et al. 2011. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J. Immunol. 186: 4234-4243.
22. Derenzini, E., M. Lemoine, D. Buglio, H. Katayama, Y. Ji, R. E. Davis, S. Sen, and A. Younes. 2011. The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. Blood Cancer J. 1: e46.
23. Yarilina, A., K. Xu, C. Chan, and L. B. Ivashkiv. 2012. Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. Arthritis Rheum. 64: 3856-3866.
24. Pattison, M. J., K. F. Mackenzie, and J. S. Arthur. 2012. Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback. J. Immunol. 189: 2784-2792.
25. Wang, H., J. Brown, S. Gao, S. Liang, R. Jotwani, H. Zhou, J. Suttles, D. A. Scott, and R. J. Lamont. 2013. The role of JAK-3 in regulating TLR-mediated inflammatory cytokine production in innate immune cells. J. Immunol. 191: 1164-1174.
26. Mishra, J., R. K. Verma, G. Alpini, F. Meng, and N. Kumar. 2015. Role of Janus Kinase 3 in predisposition to obesity-associated metabolic syndrome. J. Biol. Chem. 290: 29301-29312.
27. Martinez, F. O., S. Gordon, M. Locati, and A. Mantovani. 2006. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J. Immunol. 177: 7303-7311.
28. Hedl, M., and C. Abraham. 2011. Secretory mediators regulate Nod2-induced tolerance in human macrophages. Gastroenterology 140: 231-241.
29. O'Shea, J. J., A. Kontzias, K. Yamaoka, Y. Tanaka, and A. Laurence. 2013. Janus kinase inhibitors in autoimmune diseases. Ann. Rheum. Dis. 72(Suppl 2): ii111-ii115.
30. Franchi, L., N. Kamada, Y. Nakamura, A. Burberry, P. Kuffa, S. Suzuki, M. H. Shaw, Y. G. Kim, and G. Núñez. 2012. NLRC4-driven production of IL-1b discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. Nat. Immunol. 13: 449-456.
31. Hedl, M., and C. Abraham. 2012. Nod2-induced autocrine interleukin-1 alters signaling by ERK and p38 to differentially regulate secretion of inflammatory cytokines. Gastroenterology 143: 1530-1543.
32. Dai, L., K. B. Lidie, Q. Chen, J. W. Adelsberger, X. Zheng, D. Huang, J. Yang, R. A. Lempicki, T. Rehman, R. L. Dewar, et al. 2013. IL-27 inhibits HIV-1 infection in human macrophages by down-regulating host factor SPTBN1 during monocyte to macrophage differentiation. J. Exp. Med. 210: 517-534.
33. Guzzo, C., A. Ayer, S. Basta, B. W. Banfield, and K. Gee. 2012. IL-27 enhances LPS-induced proinflammatory cytokine production via upregulation of TLR4 expression and signaling in human monocytes. J. Immunol. 188: 864-873.
34. Dowty, M. E., J. Lin, T. F. Ryder, W. Wang, G. S. Walker, A. Vaz, G. L. Chan, S. Krishnaswami, and C. Prakash. 2014. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. Drug Metab. Dispos. 42: 759-773.
35. Krishnaswami, S., V. Chow, M. Boy, C. Wang, and G. Chan. 2014. Pharmaco-kinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease. J. Clin. Pharmacol. 54: 46-52.
36. Verstovsek, S., H. Kantarjian, R. A. Mesa, A. D. Pardanani, J. Cortes-Franco, D. A. Thomas, Z. Estrov, J. S. Fridman, E. C. Bradley, S. Erickson-Viitanen, et al. 2010. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med. 363: 1117-1127.
37. Mishra, J., R. K. Verma, G. Alpini, F. Meng, and N. Kumar. 2013. Role of Janus kinase 3 in mucosal differentiation and predisposition to colitis. J. Biol. Chem. 288: 31795-31806.
38. Vermeire, S., S. Schreiber, R. Petryka, T. Kuehbacher, X. Hebuterne, X. Roblin, M. Klopocka, E. Goldis, M. Wisniewska-Jarosinska, A. Baranovsky, et al. 2016. Filgotinib (GLPG0634), an oral JAK1 selective inhibitor, induces clinical remission in patients with moderate-to-severe crohn's disease: results from the Phase 2 Fitzroy study interim analysis. Gastroenterology 150: S1267.
39. Ulrich, C. M., Y. Yasui, R. Storb, M. M. Schubert, J. L. Wagner, J. Bigler, K. S. Ariail, C. L. Keener, S. Li, H. Liu, et al. 2001. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 98: 231-234.
40. Aithal, G. P., C. P. Day, P. J. Kesteven, and A. K. Daly. 1999. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353: 717-719.
41. Rutz, S., X. Wang, and W. Ouyang. 2014. The IL-20 subfamily of cytokines-from host defence to tissue homeostasis. Nat. Rev. Immunol. 14: 783-795.
42. Ziegler, S. F., and D. Artis. 2010. Sensing the outside world: TSLP regulates barrier immunity. Nat. Immunol. 11: 289-293.